Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100SUJL
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥32.3bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥1.4bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥36.9bnat 2023-12-31Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.3bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥11.1bnat 2023-12-31Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥25.8bnat 2023-12-31Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥115.042023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.32023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥114.582023-04-01 → 2023-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio69.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥377m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.1bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥661m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥71m
—segment totalrevenue2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥0
—segment totalsegment profit2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥170m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 363
ItemContextValueUnit
Subscription rights to sharesPrior1YearInstant82000000JPY
Subscription rights to sharesCurrentQuarterInstant78000000JPY
Net assetsPrior1YearInstant26591000000JPY
Net assetsCurrentQuarterInstant25764000000JPY
Liabilities and net assetsPrior1YearInstant38893000000JPY
Liabilities and net assetsCurrentQuarterInstant36868000000JPY
Net salesPrior1YTDDuration35878000000JPY
Net salesCurrentYTDDuration32314000000JPY
Cost of salesPrior1YTDDuration24569000000JPY
Cost of salesCurrentYTDDuration22599000000JPY
Gross profitPrior1YTDDuration11308000000JPY
Gross profitCurrentYTDDuration9715000000JPY
Selling general and administrative expensesPrior1YTDDuration8798000000JPY
Selling general and administrative expensesCurrentYTDDuration8271000000JPY
Operating incomePrior1YTDDuration2509000000JPY
Operating incomeCurrentYTDDuration1443000000JPY
Dividends income noiPrior1YTDDuration115000000JPY
Dividends income noiCurrentYTDDuration91000000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration0JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration1000000JPY
Other noiPrior1YTDDuration89000000JPY
Other noiCurrentYTDDuration65000000JPY
Non operating incomePrior1YTDDuration205000000JPY
Non operating incomeCurrentYTDDuration157000000JPY
Interest expenses noePrior1YTDDuration14000000JPY
Interest expenses noeCurrentYTDDuration6000000JPY
Commission fee noePrior1YTDDuration4000000JPY
Commission fee noeCurrentYTDDuration4000000JPY
Loss on insurance cancellation noePrior1YTDDuration0JPY
Loss on insurance cancellation noeCurrentYTDDuration11000000JPY
Other noePrior1YTDDuration3000000JPY
Other noeCurrentYTDDuration18000000JPY
Non operating expensesPrior1YTDDuration22000000JPY
Non operating expensesCurrentYTDDuration41000000JPY
Ordinary incomePrior1YTDDuration2692000000JPY
Ordinary incomeCurrentYTDDuration1559000000JPY
Gain on sales of investment securities eiPrior1YTDDuration142000000JPY
Gain on sales of investment securities eiCurrentYTDDuration346000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1000000JPY
Gain on reversal of asset retirement obligations eiPrior1YTDDuration－JPY
Gain on reversal of asset retirement obligations eiCurrentYTDDuration68000000JPY
Extraordinary incomePrior1YTDDuration142000000JPY
Extraordinary incomeCurrentYTDDuration415000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration5000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration16000000JPY
Loss on valuation of investment securities elPrior1YTDDuration18000000JPY
Loss on valuation of investment securities elCurrentYTDDuration－JPY
Impairment loss elPrior1YTDDuration110000000JPY
Impairment loss elCurrentYTDDuration0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass